¶ prostaglandin
Prostaglandins are 20-carbon lipid signaling molecules synthesized from arachidonic acid via cyclooxygenase (COX-1 and COX-2) enzymes. They orchestrate acute inflammation by mediating vasodilation, vascular permeability, fever induction, and nociceptor sensitization, while simultaneously initiating the tissue repair cascade essential for proper resolution of inflammation.
Think of prostaglandins as the emergency broadcast system for a neighborhood under attack. When tissue damage occurs, phospholipase A2 rips open the cell membrane (like breaking the glass on a fire alarm) to release arachidonic acid. This raw signal is then processed by two different radio stations: COX-1 (the 24/7 emergency broadcast station always on the air for routine maintenance alerts) and COX-2 (the specialized emergency station that fires up only during the crisis). These stations convert the raw signal into specific emergency messages—PGE2 cranks up the pain volume so you know something's wrong, PGI2 dilates blood vessels like opening highway lanes for ambulances, PGD2 tells the body to rest and sleep during recovery. Taking NSAIDs is like shutting down both radio stations during the fire—yes, you stop hearing the alarm (pain reduction), but you also prevent the emergency crews (neutrophils, repair factors) from getting their coordination signals. The building might burn down quietly, and what should have been a controlled, acute response becomes a smoldering chronic problem because nobody got the signal to come clean up properly.
graph TD
A["Cell membrane damage/<br/>immune activation"] --> B[Phospholipase A2 activation]
B --> C[Arachidonic acid release]
C --> D["COX-1<br/>constitutive"]
C --> E["COX-2<br/>inducible by<br/>NF-κB, IL-1β, TNF-α"]
D --> F[PGH2]
E --> F
F --> G["Tissue-specific<br/>prostaglandin synthases"]
G --> H[PGE2]
G --> I["PGI2<br/>prostacyclin"]
G --> J[PGD2]
G --> K["PGF2α"]
H --> L["Fever via<br/>hypothalamic EP3"]
H --> M["Nociceptor sensitization<br/>EP1/EP2 receptors"]
H --> N["Neutrophil recruitment<br/>& activation"]
I --> O["Vasodilation via<br/>IP receptors"]
I --> P[Platelet inhibition]
J --> Q["Inflammatory cell<br/>infiltration"]
J --> R["Sleep promotion<br/>DP1 receptors"]
K --> S["Smooth muscle<br/>contraction"]
The cascade initiates when PAMPs, DAMPs, or Xamps activate phospholipase A2 (PLA2), which cleaves arachidonic acid from membrane phospholipids. Two distinct COX enzyme isoforms then process this substrate:
COX-1 pathway (constitutive):
- Continuously expressed in most tissues at low baseline levels
- Maintains homeostatic functions: gastric mucosal protection, platelet function, renal blood flow
- Produces PGE2, PGI2 at physiological concentrations (typically <1-5 pg/mL in plasma)
COX-2 pathway (inducible):
- Transcriptionally upregulated within 1-4 hours by NF-kB, IL-1β, TNF-α, and IL-6
- Expression peaks at 8-24 hours post-injury
- Can increase prostaglandin production 10-100 fold during acute inflammation
- Subject to feedback regulation via SOCS3 and resolution mediators
Both COX enzymes convert arachidonic acid to the unstable intermediate prostaglandin H2 (PGH2, half-life ~5 minutes), which tissue-specific synthases then convert into functionally distinct prostaglandins:
PGE2 (via PGE synthases):
- Binds four E-prostanoid receptors (EP1-4) with distinct signaling:
- EP1 → Gq → ↑ intracellular Ca²⁺ → nociceptor sensitization (lowers action potential threshold by ~15-20 mV)
- EP2/EP4 → Gs → ↑ cAMP → vasodilation, neutrophil chemotaxis, fever via hypothalamic OVLT
- EP3 → Gi → ↓ cAMP → modulation of neurotransmitter release
- Peak plasma levels during acute inflammation: 50-500 pg/mL (baseline: 5-20 pg/mL)
- Induces COX-2 expression (positive feedback loop, terminated by resolvins)
- Essential for transitioning from inflammatory to proliferative phase in wound healing
PGI2/Prostacyclin (via prostacyclin synthase):
PGD2 (via hematopoietic or lipocalin-type PGD synthase):
- Binds DP1 and DP2 (CRTH2) receptors
- Promotes mast cell activation and eosinophil chemotaxis
- Sleep-inducing via adenosine pathway in CNS
- Converted to 15-deoxy-Δ12,14-PGJ2 → activates PPAR signaling → anti-inflammatory genomic effects
PGF2α (via PGF synthase):
- FP receptor activation → Gq → smooth muscle contraction
- Role in parturition, luteolysis, bronchoconstriction
NSAID mechanism of action:
Aspirin irreversibly acetylates Ser530 in COX-1 and Ser516 in COX-2, completely blocking prostaglandin synthesis for the enzyme's lifetime. Non-aspirin NSAIDs (ibuprofen, naproxen, diclofenac) competitively inhibit the COX active site with IC50 values ranging 0.1-10 μM. COX-2 selective inhibitors (celecoxib) preferentially block the inducible isoform (COX-2:COX-1 selectivity ~10-20:1). Crucially, blocking prostaglandin synthesis during the acute inflammatory phase (first 48-72 hours post-injury) prevents the neutrophil-mediated debris clearance and proper transition to resolution of inflammation via specialized pro-resolving mediators.
The prostaglandin paradox: What conventional medicine views as "pathological inflammation" (pain, swelling, fever) is actually the protective acute response essential for preventing chronic disease. This directly addresses the mismatch paradigm—our evolutionary biology expects brief, intense inflammatory events followed by complete resolution. Blocking this cascade creates evolutionary mismatch disease.
Chronic pain amplification by NSAIDs:
Multiple clinical studies demonstrate that NSAID use during acute injury (first 2-6 weeks) increases chronic pain prevalence at 6-12 months by 2-5 fold. The mechanism: PGE2 is required for neutrophil extravasation and activation. Without adequate neutrophil infiltration, damaged tissue and cellular debris accumulate, creating a persistent low-grade inflammatory stimulus. This prevents the acute inflammatory response from completing its evolutionary program and transitioning to resolution of inflammation. The selfish immune system interprets incomplete resolution as ongoing threat, maintaining sensitization of nociceptor pathways and central pain processing via dorsal horn wind-up.
Clinical thresholds and biomarkers:
- Plasma PGE2 >50 pg/mL indicates active acute inflammation
- Urinary PGE2 metabolites (PGE-M) >1000 ng/mg creatinine suggests systemic inflammatory activation
- CSF PGE2 >20 pg/mL correlates with neuroinflammation and fever response
- COX-2 expression peaks 12-24 hours post-injury; early NSAID administration during this window maximally disrupts resolution
Relevant patient populations:
- Acute musculoskeletal injury: Avoid NSAIDs during first 48-72 hours; consider ice, compression, appropriate loading instead
- Chronic pain syndromes: History of NSAID use during initial injury is a red flag for incomplete resolution
- Inflammatory bowel disease: COX-1 inhibition disrupts mucosal protection; COX-2 inhibition may impair mucosal healing
- Cardiovascular disease: COX-2 inhibition reduces protective PGI2 without affecting prothrombotic thromboxane (COX-1), increasing MI risk
- Chronic kidney disease: Prostaglandins maintain renal blood flow; NSAID use accelerates progression
Metamodel integration:
- Metamodel 1 (Evolutionary mismatch): Chronic NSAID availability creates a mismatch—our biology evolved without the ability to block acute inflammation
- Metamodel 3 (Selfish systems): Blocking the selfish immune system's primary communication network prevents proper threat assessment and resource allocation
- Metamodel 4 (Chronic activation): Incomplete acute response → persistent low-grade activation → metabolic exhaustion
- Metamodel 5 (Resolution biology): Prostaglandins are essential for initiating the switch to specialized pro-resolving mediators (resolvins, maresins)
Intervention implications:
Rather than blocking prostaglandins, support their proper temporal pattern:
- Acute phase (0-72h): Allow natural PGE2 surge; manage pain with ice, compression, controlled movement
- Resolution phase (3-14 days): Support lipid mediator class switching with omega-3 substrate (EPA 2-4g/d, DHA 1-2g/d)
- Chronic inflammation: If prostaglandin-driven symptoms persist >2 weeks, investigate incomplete resolution rather than simply suppressing with NSAIDs
- COX-1 is constitutively expressed; COX-2 is induced 10-100 fold during inflammation via NF-kB activation
- PGE2 sensitizes nociceptors by reducing action potential threshold ~15-20 mV through EP1 receptor → ↑ intracellular Ca²⁺
- Baseline plasma PGE2: 5-20 pg/mL; acute inflammation: 50-500 pg/mL; sepsis: >1000 pg/mL
- Aspirin irreversibly acetylates COX enzymes; effect lasts 7-10 days (platelet lifespan)
- NSAID use during acute injury (first 48-72h) increases 6-month chronic pain risk by 200-500%
- PGE2 is essential for neutrophil recruitment—blocking it prevents debris clearance and proper resolution
- Fever induction occurs via PGE2 acting on EP3 receptors in hypothalamic circumventricular organs (no blood-brain barrier)
- COX-2 expression peaks 8-24 hours post-injury; this is the critical window for resolution programming
- PGI2 (prostacyclin) synergizes with nitric oxide for endothelial protection and vasodilation
- Aspirin at low dose (75-100mg/d) selectively inhibits platelet COX-1 while triggering aspirin-triggered resolvins via COX-2 COX-2 acetylation
- PGD2 metabolite 15-deoxy-Δ12,14-PGJ2 activates PPAR signaling → genomic anti-inflammatory effects after acute phase
- arachidonic acid — immediate precursor released from membrane phospholipids by phospholipase A2
- cyclooxygenase — enzyme superfamily that converts arachidonic acid to PGH2 intermediate
- COX-1 — constitutive isoform maintaining homeostatic prostaglandin production
- COX-2 — inducible isoform upregulated by NF-kB, IL-1β, TNF-α during acute inflammation
- NSAIDs — block both COX isoforms, preventing prostaglandin synthesis and disrupting resolution
- phospholipase A2 — releases arachidonic acid from cell membranes in response to DAMPs/PAMPs
- acute inflammatory response — prostaglandins are primary mediators of the protective acute phase
- chronic pain — NSAID-induced suppression of acute prostaglandin response predisposes to chronicity
- nociceptor — sensitized by PGE2 via EP1 receptor reducing action potential threshold
- neutrophil — recruitment and activation depends on PGE2 signaling via EP2/EP4 receptors
- vasodilation — mediated by PGI2 and PGE2 via EP2/EP4 → cAMP → smooth muscle relaxation
- vascular permeability — prostaglandins increase endothelial gap formation allowing immune cell extravasation
- fever — PGE2 acts on EP3 receptors in hypothalamic OVLT to raise thermal set point
- specialized pro-resolving mediators — prostaglandins initiate the switch to SPM synthesis via lipid mediator class switching
- resolvins — COX-2-derived EPA/DHA metabolites that terminate prostaglandin signaling
- aspirin — irreversibly acetylates COX-2, redirecting enzyme to produce aspirin-triggered resolvins
- wound healing — prostaglandins essential for transitioning from inflammatory to proliferative phase
- resolution of inflammation — PGE2 upregulates 15-PGDH (prostaglandin-degrading enzyme) and SPM synthesis
- mast cell — release preformed prostaglandins during degranulation, amplify acute response
- Substance P — synergizes with prostaglandins in neurogenic inflammation and central sensitization
- bradykinin — co-released during tissue damage, potentiates prostaglandin-mediated pain
- histamine — acts synergistically with prostaglandins for vasodilation and vascular permeability
- NF-kB — master transcription factor inducing COX-2 expression during acute inflammation
- IL-6 — both induces COX-2 and is induced by PGE2 (bidirectional amplification loop)
- haemostasis — PGI2 inhibits platelet aggregation while thromboxane A2 (also COX-derived) promotes it
- immune system — prostaglandins regulate leukocyte trafficking, activation state, and resolution signaling
- hypothalamus — PGE2 target for fever induction and stress axis activation
- central sensitization — prostaglandin-mediated nociceptor sensitization contributes to dorsal horn wind-up
- microbiome — gut dysbiosis increases LPS → ↑ COX-2 → systemic prostaglandin elevation
- metabolic syndrome — chronic low-grade prostaglandin elevation contributes to insulin resistance
- Module 1 — Immune system fundamentals, inflammatory cascade, PAMPs/DAMPs
- Module 4 — Pain mechanisms, nociceptor sensitization, acute vs chronic pain
- Module 5 — Wound healing phases, tissue repair, resolution biology